Curr Diab Rep (2017) 17:84 DOI 10.1007/s11892-017-0914-z PATHOGENESIS OF TYPE 1 DIABETES (A PUGLIESE, SECTION EDITOR) 1 1 Tobias Neef & Stephen D. Miller Springer Science+Business Media, LLC 2017 Abstract Introduction Purpose of Review The current standard therapy for type 1 diabetes (T1D) is insulin replacement. Autoimmune diseases Type 1 diabetes (T1D) is an autoimmune disease in which are typically treated with broad immunosuppression, but this cells of the immune system destroy the insulin-producing β has multiple disadvantages. Induction of antigen-specific tol- cells located in the pancreatic islets of Langerhans. Disease erance is preferable. The application of nanomedicine to the onset can occur at any time, but most often happens at 5– problem of T1D can take different forms, but one promising 7 years of age or puberty, and there are about 280 million cases way is the development of tolerogenic nanoparticles, the aim worldwide today [1, 2]. Currently, the most common therapy of which is to mitigate the islet-destroying autoimmunity. We for T1D is insulin replacement [1–3]. Unfortunately, insulin review the topic and highlight recent strategies to produce replacement is not without its drawbacks. The discomfort of tolerogenic nanoparticles for the purpose of treating T1D. subcutaneous injection and
Current Diabetes Reports – Springer Journals
Published: Aug 8, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera